357 | Jeff Coller on mRNA, Vaccines, and Bespoke Therapeutics

Episode Summary

Executive Summary: The episode explains how mRNA technology works, why it enabled rapid COVID-19 vaccine development, and how it is now being combined with CRISPR/base editing to create personalized therapies that can correct mutations inside the body. Jeff Coller argues that delivery remains the key challenge, but the platform could transform treatment for rare diseases, cancer, and possibly other conditions soon.

Main Topics: How RNA, mRNA, DNA, and ribosomes work (Priority: 5/5): The conversation lays out the basic flow of genetic information: DNA stores instructions, mRNA carries a gene’s message, and ribosomes read mRNA to build proteins. Coller uses recipe/library/cook analogies to clarify transcription and translation. Why mRNA vaccines were transformative for COVID-19 (Priority: 5/5): Sean Carroll and Coller discuss how mRNA vaccines let cells temporarily produce a foreign protein, training immune memory without long-term persistence. Their rapid design and manufacturing made them ideal for pandemic response. RNA biology, evolution, and the RNA world hypothesis (Priority: 3/5): The transcript covers RNA’s chemical flexibility, its ability to catalyze reactions, and why scientists believe RNA likely preceded DNA in early life. The ribosome itself is partly RNA, reinforcing RNA’s ancient role. Codons, redundancy, and translation speed (Priority: 4/5): The genetic code’s 4-letter, 3-base codon system yields 64 codons for 20 amino acids plus stop signals. Coller explains codon degeneracy and how tRNA abundance affects translation speed and mRNA stability. mRNA delivery and lipid nanoparticles (Priority: 5/5): A major practical challenge is getting mRNA into the right cells. The current solution uses lipid nanoparticles, which work well for immune cells and the liver but poorly for organs like brain, pancreas, heart, and lungs. CRISPR/base editing plus mRNA for in vivo gene repair (Priority: 5/5): The episode highlights the merger of mRNA with CRISPR-based base editors to temporarily deliver gene-editing machinery, enabling direct correction of mutations inside the body rather than only outside it. Clinical promise: rare disease and cancer applications (Priority: 5/5): Examples include KJ Muldoon’s liver disorder treated with personalized gene editing and mRNA-based personalized cancer vaccines for pancreatic cancer. The discussion frames these as proof-of-concept for broader future therapies.

Key Arguments: mRNA is a natural, temporary information carrier that cells can use to make any chosen protein, making it ideal for vaccines and therapeutics. mRNA vaccines were developed so quickly during COVID-19 because the sequence can be designed in hours and manufactured in weeks, unlike protein vaccines that can take years. The main bottleneck for mRNA and gene-editing therapies is delivery to the correct cell type, not the editing or design itself. Combining mRNA with CRISPR/base editing creates a safer, more transient way to perform gene correction because the editing machinery disappears after use. Rare diseases become economically tractable when therapies can be designed quickly and personalized, unlike old blockbuster-drug development models. Cancer can be targeted by identifying neoantigens—mutated proteins unique to a tumor—and encoding them in mRNA to train the immune system. Regulatory systems and public policy have not yet adapted to individualized, one-patient therapies, so both FDA frameworks and commercialization models need updating. Demonization of mRNA technology is counterproductive because the platform is both therapeutically valuable and potentially essential for rapid biodefense countermeasures.

Data Points: Human genes: ~25,000 - Coller explains that each gene can correspond to an mRNA transcript. Genetic code letters: 4 - DNA/RNA use four nucleotide letters to encode protein information. Amino acids used in proteins: 20 - The standard set encoded by the genetic code. Possible codons: 64 - Three-base codons from four letters produce 64 combinations. Stop codons: 3 - Three codons serve as punctuation marks ending protein synthesis. Ribosomes per cell: ~500,000 - Coller estimates roughly half a million ribosomes in a human cell. FDA trials of mRNA technologies before COVID: Over 100 - Human trials were already underway before the pandemic. Vaccine development time (traditional): 10-15 years - Typical timeline for protein-based vaccine development. mRNA design time: Hours - Sequence design can be done rapidly on a computer once a target is known. mRNA manufacturing time: Weeks - Scaling up production is much faster than for protein vaccines. mRNA half-life: Hours - mRNA degrades quickly after being delivered and read. Genome sequencing cost today: A couple hundred dollars - Used to emphasize how far sequencing technology has advanced. Human Genome Project cost: Over $1 billion - Contrasted with today’s cheap sequencing. Ultra-rare CPS1 deficiency incidence: ~1 in 1.3 million - KJ Muldoon’s condition discussed as a proof-of-concept case. Genetic diseases affecting humans: Over 7,000 - Used to illustrate how many conditions could eventually be addressed. People with some genetic disease: 1 in 13 - Shows genetic disease is common overall, even if individual disorders are rare. Pancreatic cancer response in trial: 50% - Small Nature study cited where half of treated patients responded. Pancreatic cancer mortality: ~95% within a year - Used to highlight the seriousness of the disease and the promise of the therapy. CHOP/KJ treatment timing: Within a few months of birth - The baby was treated rapidly after diagnosis. Dosing frequency for KJ: 3 doses - The therapy was administered in stages. Potential improvement threshold: 10-15% - Coller notes some therapies may only need modest correction to help patients. China share of mRNA vaccine development: 46% - Coller says nearly half of mRNA-based vaccines are now being developed in China.

Pivotal Quotes: "mRNA is destroyed after reading." — Jeff Coller: Explaining why mRNA therapies are transient and potentially safer for gene editing. "If we can do it for him, we can do it for one of any ultra-rare genetic disorders or more common genetic disorders in the future." — Jeff Coller: Referring to baby KJ Muldoon’s successful personalized liver-directed gene correction. "Necessity is the mother of invention." — Sean Carroll: Used in the discussion of why better delivery systems and policy changes are urgently needed.

Implications: mRNA and CRISPR-based medicines could make personalized, one-patient therapies practical for rare diseases, cancer, and possibly common disorders, but progress depends on better delivery systems, updated regulation, and sustained public investment.